Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

½ÅÀ̽ÄÈÄ °íÇ÷¾ÐÀÌ À̽ĽŠ»ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿µÇâ Hypertension in Kidney Transplantation Recipients - Effect on Long-term Renal Allograft Survival -

´ëÇѽÅÀåÇÐȸÁö 1997³â 16±Ç 3È£ p.551 ~ 557
¼Ò¼Ó »ó¼¼Á¤º¸
¼®ÁØ/Jun Suk ±ÇÁø°æ/¹Ú¼º¹è/±èÇöö/Á¶¿øÇö/¹ÚöÈñ/Jin Kyong Kwon/Sung Bae Park/Hyun Chul Kim/Won Hyun Cho/Cheol Hee Park

Abstract

¿ä¾à
1982³â 11¿ùºÎÅÍ 1995³â 9¿ù±îÁö °è¸íÀÇ´ë µ¿»êº´¿ø¿¡¼­ ½ÅÀ̽ÄÀ» ¹Þ¾Ò´ø 335¿¹ °¡¿îµ¥
½ÅÀÌ½Ä ÈÄ 6°³¿ù ÀÌ»ó °æ°ú °üÂûÀÌ °¡´ÉÇÏ¿´´ø 319¿¹¸¦ ´ë»óÀ¸·Î ½ÅÀÌ½Ä ÈÄ °íÇ÷¾ÐÀÌ À̽Ä
½Å »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú¸¦ ¾ò¾ú´Ù. ´ë»óȯÀÚÀÇ Æò±Õ¿¬·ÉÀº 32.9
¡¾10.4¼¼(7-62)¿´°í, ¼ºº°Àº ³²ÀÚ 231¿¹, ¿©ÀÚ 88¿¹À̾ú´Ù. ÀÌÁß¿¡¼­ 20´ë°¡ ÀüüÀÇ 38.9%·Î
°ÅÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ¿´´Ù. ¸é¿ª¾ïÁ¦Á¦·Î´Â ¸ðµç ȯÀÚ°¡ cyclosporine (CsA)¿Í Àú¿ë·®ÀÇ
prednisolone(PDN)À» º¹¿ëÇÏ¿´´Ù. ½ÅÀÌ½Ä ´ç½Ã °íÇ÷¾ÐÀº 229¿¹(72%)¿¡¼­ °üÂûµÇ¾ú°í, 90¿¹
(28%)¿¡¼­´Â ½ÅÀÌ½Ä ´ç½Ã Ç÷¾ÐÀÌ Á¤»óÀ̾ú´Ù. ½ÅÀ̽ÄÈÄ °íÇ÷¾ÐÀÇ ¹ß»ýºóµµ´Â ÀÌ½Ä ÈÄ 1³â,
3³â, 5³â¿¡¼­ °¢°¢ 68%, 65%, 61%·Î ½Ã°£ÀÌ °æ°úÇÒ¼ö·Ï Á¡ÁøÀûÀ¸·Î °¨¼ÒµÇ¾ú´Ù(p<0.05).
½ÅÀ̽ÄÈÄ °íÇ÷¾Ð±º°ú Á¤»ó Ç÷¾Ð±º»çÀÌ¿¡¼­ üÁßÀÇ Áõ°¡´Â ½ÅÀ̽ÄÈÄ 1³â, 3³â, 5³â¿¡¼­ À¯
ÀÇÇÏ°Ô Áõ°¡µÇ¾úÀ¸¸ç(p<0.05), Ç÷û creatinineÄ¡´Â ¾ç±º»çÀÌ¿¡ À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ½ÅÀÌ
½ÄÈÄ °íÇ÷¾Ð±º¿¡¼­ »ç¿ëÇÏ°í ÀÖ´Â Ç×°íÇ÷¾Ð ¾àÁ¦¼ö¿¡ À־µµ ½ÅÀÌ½Ä Á÷ÈÄ ´ç½Ã 1.35¡¾1.09
°³¿¡¼­ ½ÅÀÌ½Ä 1³â ÈÄ 0.98¡¾0.76°³·Î À¯ÀÇÇÏ°Ô °¨¼ÒµÇ¾ú´Ù(p<0.05). ½ÅÀ̽ÄÈÄ °íÇ÷¾ÐÀÌ ¾ÇÈ­
¶Ç´Â Áö¼ÓµÈ °æ¿ì°¡ 80¿¹(25%)¿´°í »õ·ÎÀÌ °íÇ÷¾ÐÀÌ ¹ß»ýÇÑ °ÍÀº 26¿¹(8%)¿´À¸¸ç, ±× ¿øÀÎ
À¸·Î´Â °ÅºÎ ¹ÝÀÀ ¶Ç´Â ¿øÀÎ ÁúȯÀÇ Àç¹ßÀÌ 52¿¹(49%)·Î °¡Àå ¸¹¾Ò°í, PDN ¹× CsA¿Í °°
Àº ¸é¿ª¾ïÁ¦Á¦ »ç¿ëÀÌ 31¿¹(29%), ¿øÀÎ ¹Ì»ó ¶Ç´Â º»·¡ÀÇ ½ÅÀå¿¡¼­ ±âÀÎµÈ °æ¿ì 21¿¹(20%),
À̽ĽŠµ¿¸ÆÇùÂø 2¿¹(2%)ÀÇ ¼øÀ̾ú´Ù. ½ÅÀ̽ÄÈÄ °íÇ÷¾Ð±ºÀ» Ç÷¾ÐÁ¶Àý À¯¹«¿¡ µû¶ó ºñÁ¶Àý±º
(n=53), Á¶Àý±º(n=176)À¸·Î ³ª´©¾ú°í Á¤»ó Ç÷¾Ð±º(n=90)°úÀÇ ÃßÀû°üÂû ±â°£ Áß À̽ĽŠ±â´É
¼Ò½Ç·üÀ» ºñ±³Çغ¸¸é, Ç÷¾Ð ºñÁ¶Àý±º°ú Á¶Àý±ºÀÇ À̽ĽŠ±â´É¼Ò½Ç·üÀº (66% vs. 30%,
p<0.001)·Î Ç÷¾ÐºñÁ¶Àý±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾ÒÀ¸³ª Ç÷¾ÐÁ¶Àý±º°ú Á¤»óÇ÷¾Ð±º »çÀÌ¿¡´Â À¯ÀÇÇÑ
Â÷ÀÌ°¡ ¾ø¾ú´Ù(30% vs. 20%, p=NS). ½ÅÀ̽ÄÈÄ ½Ã°£°æ°ú¿¡ µû¸¥ Ç÷û creatinineÄ¡ÀÇ º¯È­´Â
Ç÷¾ÐÁ¶Àý±º°ú Á¤»óÇ÷¾Ð±º¿¡ ºñÇØ Ç÷¾ÐºñÁ¶Àý±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(p<0.001). 5³â À̽ĽÅ
»ýÁ¸À²µµ Á¤»óÇ÷¾Ð±º°ú Ç÷¾ÐÁ¶Àý±º»çÀÌ¿¡´Â À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾úÀ¸³ª(44% vs. 50%, p=NS),
Ç÷¾ÐºñÁ¶Àý±ºÀÌ 20%·Î Ç÷¾ÐÁ¶Àý±º ¹× Á¤»óÇ÷¾Ð±ºº¸´Ù À¯ÀÇÇÏ°Ô ³·¾Ò´Ù. ±×·¯³ª ȯÀÚ »ýÁ¸
·ü¿¡ À־´Â °¢ ±º »çÀÌ¿¡ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ÀÌ»óÀÇ ¼ºÀûÀ» Á¾ÇÕÇÏ¸é ½ÅÀ̽ÄÈÄ °íÇ÷¾Ð À¯¹«
ÀÚüº¸´Ù´Â Ç÷¾ÐÀÇ Á¶Àý¿©ºÎ°¡ À̽ĽŠ»ýÁ¸À²¿¡ À¯ÀÇÇÑ ¿µÇâÀ» ¹ÌÃÆ´Ù. µû¶ó¼­ ½ÅÀ̽ÄÈÄ °í
Ç÷¾ÐÀ» ¾ö°ÝÈ÷ Á¶ÀýÇÔÀ¸·Î½á À̽ĽÅÀÇ ±â´ÉÀúÇϸ¦ ¸·À» ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÈ´Ù.
#ÃÊ·Ï#
Hypertension is a frequent complication after organ transplantation and remains risk
factor for the development of cardiovascular disease and graft dysfunction after renal
transplantation. The prevalence of hypertension after renal transplantation varies from
50% to 93%. There are multiple mechanisms for development of post-transplant
hypertension.
To examine the effects of hypertension on renal allograft survival, we studied the
clinical course of 319 kidney transplant recipients (male : female=231 : 88, mean age=32.5
¡¾10.4 yrs) who had functioning graft at least 6 months. The patients were divided into
three groups : normotensive groups(n=90), controlled hypertensive groups(n=176) and
uncontrolled hypertensive groups(n=53).
Anions 319 patients, 229(72%) were hypertensive at the time of renal transplantation.
The incidence of hypertension decreased progressively to 68%, 65% and 61% at 1, 3 and
5 years after transplantation (p<0.05). The numbers of antihypertensive medication at
the time of operation was 1.35¡¾1.09, which decreased significantly to 0.98¡¾0.76 at 12
months after renal transplantation(p<0.05).
Cumulative graft survival at 5 years for normotensive and controlled hypotensive
patients were 44% and 50% respectively, 20% for uncontrolled hypertensive patients.
The difference of 5 years graft survival between controlled hypertensive and
uncontrolled hypertensive patients was significant (p<0.01), whereas the difference
between the normotensive and controlled hypertensive group was not significant.
We conclude that hypertension per se may not be an important risk factor for renal
graft survival. However, the control of hypertension appear to be a more important risk
factor for renal allograft survival.

Å°¿öµå

Renal transplantation; Hypertension; Graft survival;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS